Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer
International Journal of Urology · 2023
DOI: 10.1111/iju.15225 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2023. Verfasst von Mohsin Shiekh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Roswell Park Alliance Foundation, Roswell Park Cancer Institute.
Abstract (Originalsprache)
Objective
To develop and validate a nomogram to improve the specificity of prostate imaging reporting and data system (PI‐RADS) on multiparametric magnetic resonance imaging (MRI) for clinically significant prostate cancer on targeted fusion biopsy.
Methods
A retrospective review of patients who underwent fusion biopsy for PI‐RADS 3–5 lesions using UroNav and Artemis systems between 2016 and 2022 was performed. Patients were divided into those with CS disease on fusion biopsy (Gleason grade group ≥2) versus those without. Multivariable analysis was used to identify variables associated with CS disease. A 100‐point nomogram was constructed, and ROC curve was generated.
Results
1485 lesions (1032 patients) were identified, 510 (34%) were PI‐RADS 3, 586 (40%) were PI‐RADS 4, and 389 (26%) were PI‐RADS 5. Of these, 11% of PI‐RADS 3, 39% of PI‐RADS 4, and 61% of PI‐RADS 5 showed CS disease. CS disease was associated with older age (OR 1.04, 95% CI 1.02–1.06, p < 0.01), previous negative biopsy (OR 0.52, 95% CI 0.36–0.74, p < 0.01), presence of multiple PI‐RADS 3–5 lesions (OR 0.61, 95% CI 0.45–0.83, p < 0.01), peripheral zone location (OR 1.88, 95% CI 1.30–2.70, p < 0.01), PSA density (OR 1.48 per 0.1 unit, 95% CI 1.33–1.64, p < 0.01), PI‐RADS score 4 (OR 3.28, 95% CI 2.21–4.87, p < 0.01), and PI‐RADS score 5 (OR 7.65, 95% CI 4.93–11.85, p < 0.01). Area under ROC curve was 82% for nomogram compared to 75% for PI‐RADS score alone.
Conclusion
We report a nomogram that combines PI‐RADS score with other clinical parameters. The nomogram outperforms PI‐RADS score for the detection of CS prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Urology, Montefiore Medical Center, Bronx, New York, USA.
ORCID-Profile: Khurshid Guru, Ahmed A Hussein
Förderung
- Roswell Park Alliance Foundation, Roswell Park Cancer Institute
Zitieren
APA
Shiekh, M., Houenstein, H., Ramahi, Y. O., Shabir, U., Ghadersohi, S., Zhu, D., Zhu, M., Jing, Z., Attwood, K., Kauffman, E., Aboumohamed, A., Guru, K., & Hussein, A. A. (2023). Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer. International Journal of Urology. https://doi.org/10.1111/iju.15225
Vancouver
Shiekh M, Houenstein H, Ramahi YO, Shabir U, Ghadersohi S, Zhu D, et al. Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer. International Journal of Urology. 2023. doi:10.1111/iju.15225
BibTeX
@article{Shiekh2023,
author = {Shiekh, Mohsin and Houenstein, Holly and Ramahi, Yousuf O and Shabir, Usma and Ghadersohi, Sarah and Zhu, Denzel and Zhu, Michael and Jing, Zhe and Attwood, Kristopher and Kauffman, Eric and Aboumohamed, Ahmed and Guru, Khurshid and Hussein, Ahmed A},
title = {Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15225}
}
EUVIMED